Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

Rallybio’s headquarters are in New Haven, Connecticut, USA, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.

Rallybio are in development of their pipeline program RLYB212. This is an investigational drug designed to prevent HPA-1a alloimmunization in expectant mothers at higher risk of FNAIT.
Read more about RLYB212 here.

NEW HAVEN, Conn.–(BUSINESS WIRE)–Mar. 6, 2023–
Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects.


For more information, please visit www.rallybio.com